Phase i trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission Academic Article uri icon

Overview

MeSH Major

  • Antigens, Neoplasm
  • Cancer Vaccines
  • Gangliosides
  • Neuroblastoma
  • beta-Glucans

abstract

  • This immunotherapy program lacks major toxicity and is transportable to any outpatient clinic. Patient outcome is encouraging but the efficacy is uncertain because of the complexity and heterogeneity of prior therapies. A larger phase II trial is underway.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5592799

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-13-1012

PubMed ID

  • 24520094

Additional Document Info

start page

  • 1375

end page

  • 82

volume

  • 20

number

  • 5